TIBET PHARMA(SH:600211) Xin Lang Zheng Quan·2025-08-22 02:41Core Viewpoint - Xizang Pharmaceutical experienced a stock price decline of 2.01% on August 22, with a current price of 45.86 CNY per share and a total market capitalization of 14.782 billion CNY [1] Group 1: Stock Performance - Year-to-date, Xizang Pharmaceutical's stock price has increased by 27.57%, with a recent decline of 2.32% over the last five trading days [1] - Over the past 20 days, the stock price has risen by 14.94%, and over the past 60 days, it has increased by 26.62% [1] Group 2: Financial Performance - For the first half of 2025, Xizang Pharmaceutical reported a revenue of 1.651 billion CNY, representing a year-on-year growth of 2.23% [2] - The net profit attributable to the parent company for the same period was 567 million CNY, showing a year-on-year decrease of 8.96% [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Xizang Pharmaceutical was 45,200, a decrease of 8.08% from the previous period [2] - The average number of tradable shares per shareholder increased by 8.79% to 7,132 shares [2] Group 4: Dividend Information - Xizang Pharmaceutical has distributed a total of 1.974 billion CNY in dividends since its A-share listing, with 1.296 billion CNY distributed over the last three years [3] Group 5: Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 2.5902 million shares, a decrease of 1.6084 million shares from the previous period [3] - Huaxia Industry Prosperity Mixed Fund (003567) was the tenth-largest circulating shareholder, maintaining its holding of 1.9036 million shares [3]